Navigation Links
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Date:5/26/2009

Data Confirm Tapentadol Efficacy and Tolerability for Acute Pain Patients

RARITAN, N.J., May 26 /PRNewswire-USNewswire/ -- It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicines during and after surgery is a leading risk factor for experiencing these side effects. Nausea and vomiting are uncomfortable and bothersome and can have an impact on a patient's recovery.

According to a new Phase 3 clinical study published in the June 2009 issue of Current Medical Research and Opinion, and in an online version of the journal, tapentadol immediate release (IR) tablets provided patients with equivalent efficacy in pain relief following orthopedic surgery and significant reduction in nausea and/or vomiting compared to oxycodone IR.

Results from the new Phase 3 study of tapentadol IR tablets, a prescription oral analgesic approved by the U.S. Food and Drug Administration (FDA) in November 2008, showed that patients receiving 50-mg or 75-mg of the medication experienced significant relief of moderate to severe acute pain after a bunionectomy, one of the most common foot surgeries, compared with placebo. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), Raritan, NJ, and Grunenthal GmbH, Aachen, Germany, supported this study.

The overall difference in the intensity of pain experienced by patients recovering from bunionectomy was examined during the first 12, 24, 48 and 72 hours after initiating treatment with tapentadol IR. Both tapentadol IR treatment groups showed a statistically significant improvement in pain compared to patients who received placebo, during all of these time periods (P <0.001), achieving both the primary efficacy endpoint of the sum of pain intensity difference (SPID) at 48 hours and secondary efficacy endpoints (SPID(12),
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
5. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
11. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ... directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... breached its fiduciary duties to shareholders. On ... investing website reporting that Advaxis had misrepresented the clinical ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... 29, 2011 The Female Health Company (Nasdaq: ... conference call to discuss its operating results for the third ... 5, 2011 at 11:00 a.m. Eastern Time (EDT).  The Company ... Shareholders and other interested parties may participate ...
... AMGN ) reported total revenue increased 4 percent ... $3,804 million in the second quarter of 2010.  Total product ... to $3,893 million versus $3,613 million in the second quarter ... quarter of 2011 included a decline in other revenue due ...
Cached Medicine Technology:The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 2Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 3Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 4Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 5Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 6Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 7Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 8Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 9Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 10Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 11Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 12Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 13Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 14Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 15Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 16Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 17Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 18Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion 19
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2
... LAKE FOREST, Ill. and MINNEAPOLIS , ... Fitness Corporation (NYSE AMEX: FIT ) today announced that ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in ...   http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , On January 21, 2010 , ...
... WASHINGTON , Feb. 5 In response ... today, the American Veterinary Medical Association (AVMA) is reaffirming its ... help maintain and improve the health of U.S. livestock. , ... creating a new strategy for animal disease traceability. This comes ...
... ... San Francisco,s famed PIER 39 docks, was successfully rescued, rehabilitated and released back to the ... assembled at Rodeo Beach in the Marin Headlands, Sausalito, CA to watch as "Abagnale" made ... ...
... focus of new laws, online testing and Super Bowl plug ... improve treatment of concussions in youth sports are making headway ... in scholastic sports will get big play Sunday at Super ... can help athletic trainers and doctors determine when it,s safe ...
... LOS ANGELES , Feb. 5 Food 4 ... to support children,s hospitals in the communities its stores serve in ... Chicago area. In addition, the supermarket chain,s Foods Co ... California . , Customers and team members can support their ...
... Finding may further understanding of common diseases, researchers say , ... map of areas of the human genome that control which ... a finding that may advance understanding of the genetic ... the human genome is uncharted territory -- entire stretches of ...
Cached Medicine News:Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4Health News:AVMA Calls for Stronger Animal Disease Traceability System 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 3Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 4Health News:Concussion Awareness for Young Athletes Gets Big Play 2Health News:Food 4 Less Charitable Campaign to Benefit Children's Hospitals 2
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
ROB-NEL Catheters (100% Latex-Free)...
Silver Foley Catheter 2-way...
Medicine Products: